Kepalb®Palbociclib Capsuless
Kepalb® Palbociclib Capsuless are an oral CDK4/6 inhibitor that selectively targets and inhibits the activity of the CDK4/6-Cyclin D1 complex. This prevents tumor cells from passing through the G1 to S phase checkpoint, blocking the cell cycle and inhibiting tumor cell proliferation.It is primarily used for the treatment of hormone receptor-positive (HR+), HER2-negative locally advanced or metastatic breast cancer, in combination with aromatase inhibitors as initial endocrine therapy for postmenopausal women.
Xinyang® Abiraterone Acetate Tablets
Xinyang® Abiraterone Acetate Tablets are a highly selective CYP17 enzyme inhibitor that targets multiple sites of androgen biosynthesis throughout the body.
Kelenva® Lenvatinib Mesilate Capsules
Lenvatinib Mesilate Capsules is an oral multi-target kinase inhibitor, primarily targeting VEGFR1-4, FGFR1-3, PDGFRα/β, c-Kit, and RET. It inhibits tumor angiogenesis, suppresses tumor cell growth, and modulates the tumor immune microenvironment. Clinically, it is used to treat unresectable hepatocellular carcinoma (uHCC). The global multi-center REFLECT study showed significant efficacy of Lenvatinib in treating uHCC. It has been included as a first-line treatment for advanced liver cancer in countries such as China, Japan, and the United States.
Kerilin®Eribulin Mesylate Injection
Kerilin®Eribulin Mesylate Injection was approved by NMPA on January 14, 2025. It is the second drug for breast cancer launched by Qingfeng Pharmaceutical Group following Palbociclib Capsules. Having passed the generic drug consistency evaluation, it is therapeutically equivalent to the originator product with a more favorable price, providing breast cancer patients with more treatment options.
Zenza® Enzalutamide Soft Capsules
Enzalutamide Soft Capsules are a medication for patients with advanced prostate cancer. It is primarily indicated for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) who are at high risk of metastasis, and for adult patients with metastatic castration-resistant prostate cancer (CRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT) and have not received chemotherapy.
Keraf®Sorafenib Tosylate Tablets
Keraf®Sorafenib Tosylate Tablets are a multi-target oral medication for treating tumors, with dual mechanisms of action. It inhibits tumor angiogenesis by blocking VEGFR and PDGFR and suppresses tumor cell proliferation by blocking the Raf/MEK/ERK signaling pathway, indirectly inhibiting tumor cell growth. It was approved for market in August 2020. It is primarily used for the treatment of renal cancer, liver cancer, and thyroid cancer.
Kegora®Regorafenib Tablets
Regorafenib is an oral multi-kinase inhibitor that targets multiple tumor signaling pathways. With a broad spectrum of targets, it inhibits both the VEGF pathway and its bypass mechanisms, effectively disrupting inter-pathway crosstalk.
Kefati® Afatinib Dimaleate Tablets
Kefati® Afatinib Dimaleate Tablets are the first irreversible ErbB family receptor blockers. They covalently bind to the kinase regions of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4), irreversibly inhibiting tyrosine kinase autophosphorylation, leading to downregulation of ErbB signaling and inhibiting tumor cell proliferation. Xinchuo® was approved for market in August 2021 and is indicated for: Locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR gene-sensitive mutations in patients who have not previously received EGFR tyrosine kinase inhibitors (TKI) treatment. Locally advanced or metastatic squamous cell carcinoma of non-small cell lung cancer (NSCLC) with disease progression during or after platinum-based chemotherapy.